文献速递湿疹皮炎与荨麻疹

急性荨麻疹治疗的系统综述

Treatment of acute urticaria: A systematic review.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-02-29

三项RCT中两项显示抗组胺药加泼尼松不优于单用抗组胺药;五项研究中两项显示苯海拉明联合雷尼替丁或西咪替丁最有效。现有证据少且质量有限,急性荨麻疹最佳管理仍不明确。

要点

  • 抗组胺药加泼尼松未显示优于单用抗组胺药。
  • 苯海拉明联合雷尼替丁或西咪替丁可能更有效。
  • 现有RCT少且样本小,需高质量试验。

核心结论

  • 仅少数小样本RCT提供急性荨麻疹治疗证据,最佳管理仍不明确。
  • 抗组胺药加皮质类固醇的获益需进一步研究。

研究设计与样本

  • 系统综述,检索PubMed和Web of Science,按PRISMA进行描述性综合。
  • 采用Cochrane偏倚风险工具独立评估RCT质量。

主要发现

  • 四项研究评估抗组胺药加皮质类固醇的效果,六项比较H1和/或H2抗组胺药疗效。
  • 三项RCT中两项显示抗组胺药加泼尼松不优于单用抗组胺药。
  • 五项研究中两项显示苯海拉明(50 mg,IV)联合雷尼替丁(50 mg,IV)或西咪替丁(300 mg,IV)缓解荨麻疹最有效。
  • 最常见不良事件为镇静和嗜睡。

关键数值与推荐

  • 泼尼松加左西替利嗪或西替利嗪未改善急性荨麻疹症状(三项RCT中两项)。
  • 苯海拉明50 mg IV联合雷尼替丁50 mg IV或西咪替丁300 mg IV在两项研究中显示最有效。

临床怎么用

  • 现有证据不支持常规在抗组胺药基础上加用皮质类固醇治疗急性荨麻疹。
  • H1联合H2抗组胺药可能考虑用于缓解症状,但需注意镇静和嗜睡。

局限性

  • 近期荨麻疹指南主要关注慢性荨麻疹而非急性荨麻疹。
  • 急性荨麻疹的最佳管理仍不明确,需高质量干预试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are only a few clinical trials which address the treatment of acute urticaria (AU). Especially, the added value of systemic corticosteroids to antihistamines is unclear in treatment of severe AU. To review the existing evidence-based approaches for AU treatment. A systematic electronic search was done in PubMed and Web of Science to retrieve all studies on the treatment of patients with AU. A descriptive synthesis was conducted based on the PRISMA statement. Quality assessment was independently performed by both reviewers ('Cochrane risk-of-bias tool' for RCTs). Ten randomized controlled trials (RCTs) (n = 857 participants) were included. Four studies assessed corticosteroid effectiveness added to antihistamines and six studies compared the efficacy of H1 and/ or H2-antihistamines. The addition of corticosteroid (prednisone) to an antihistamine (levo)cetirizine did not improve symptoms of AU compared to antihistamine alone in two out of three RCTs. The combination of diphenhydramine (50 mg, IV) and ranitidine (50 mg, IV) or cimetidine (300 mg, IV) was most efficient for relief of urticaria in two out of five studies. Most frequent adverse effects were sedation and drowsiness. Recent guidelines on urticaria treatment mainly focus on chronic urticaria rather than on AU. Moreover, only few, small RCTs provide evidence for the management of AU. Thus, the state-of-the-art management of this frequent condition remains unclear. The addition of corticosteroids to an antihistamine as treatment for AU needs to be further investigated. Well-designed, high-quality interventional trials are needed to establish evidence-based treatment guidelines for AU.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Badloe FMS, Grosber M, Ring J, et al. Treatment of acute urticaria: A systematic review. J Eur Acad Dermatol Venereol. 2024. PMID: 38420865. doi:10.1111/jdv.19904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。